Core Viewpoint - Peijia Medical-B (09996) has seen a stock price increase of 5.60% to HKD 5.85 following the announcement of the acceptance of its TAVR system registration application by the National Medical Products Administration of China [1][5]. Group 1: Company Announcement - On December 7, Peijia Medical announced that it received an acceptance notice for the registration application of its TaurusNXT® "non-glutaraldehyde cross-linked" transcatheter aortic valve replacement (TAVR) system [1][5]. - The TaurusNXT® is a third-generation TAVR system developed in-house, utilizing patented non-glutaraldehyde biological tissue cross-linking technology aimed at enhancing the durability and biocompatibility of artificial aortic valves [1][5]. Group 2: Executive Actions - The company disclosed that Dr. Zhang Yi, the Executive Director, CEO, and Chairman of the Board, plans to purchase company shares in the open market starting from December 1, 2025, with a total investment not exceeding HKD 15 million [1][5]. - This share purchase reflects Dr. Zhang's recognition of the company's intrinsic value and his strong confidence in the company's development prospects and growth potential [1][5].
沛嘉医疗-B早盘涨逾6% Taurus NXT系统注册申请获受理